高危单侧视网膜母细胞瘤的治疗结局与定义不一致性
这项回顾性多国队列研究纳入2011-2020年12国21个中心接受初始眼球摘除的视网膜母细胞瘤患儿,分析标准化高危组织病理特征(HRHF)者的结局及局部定义与标准化定义的差异。共600例中505例(84.2%)被当地视为HRHF并接受辅助化疗,36例(6.0%)眼眶复发、49例(8.2%)转移、72例(12.0%)死亡;未接受辅助化疗者眼眶复发、转移和死亡风险显著增加(P ≤ .002)。作者推荐初始眼球摘除后诊断为HRHF者使用辅助化疗,并指出全球各中心对HRHF定义存在差异,导致不良结局,需要标准化。
要点
- 600例中505例(84.2%)被当地视为HRHF并接受辅助化疗,中位随访39.2 ± 1.6个月后36例(6.0%)眼眶复发、49例(8.2%)转移、72例(12.0%)死亡。
- 未接受辅助化疗的患儿眼眶肿瘤复发、转移和死亡风险显著增加(P ≤ .002)。
- 63/600(10.5%)当地视为非HRHF但按标准化定义转为HRHF,其中6/63(9.5%)眼眶复发、5/63(7.9%)转移、6/63(9.5%)死亡。
核心结论
- 基于该多国儿童视网膜母细胞瘤队列,作者推荐初始眼球摘除后诊断为HRHF者使用辅助化疗。
- 全球各中心对HRHF定义存在差异,导致不良患者结局,需要标准化。
研究设计与样本
- 回顾性多国临床队列研究,纳入2011-2020年12国21个中心因视网膜母细胞瘤接受初始眼球摘除的患儿。
- 分析仅纳入具有标准化HRHF的单侧病例,标准化HRHF定义为:视神经筛板后浸润、大片脉络膜浸润、巩膜浸润、前节受累和/或非大片脉络膜浸润合并筛板前/筛板处视神经浸润。
- 最终分析纳入9国14个中心的600例患儿。
主要发现
- 600例中505例(84.2%)被当地视为HRHF并接受辅助化疗。
- 中位随访39.2 ± 1.6个月(范围0.8-60.0个月)后,36例(6.0%)眼眶肿瘤复发、49例(8.2%)转移、72例(12.0%)死亡。
- 未接受辅助化疗的患儿眼眶肿瘤复发、转移和死亡风险显著增加(P ≤ .002)。
- 63/600(10.5%)当地视为非HRHF但转为标准化HRHF,其中6/63(9.5%)眼眶复发、5/63(7.9%)转移、6/63(9.5%)死亡。
- 114例(19.0%)报告孤立性轻微脉络膜浸润合并筛板前/筛板处视神经浸润,其中仅68/114(59.6%)被当地视为HRHF;该114例中6例(5.3%)发生转移并随后死亡,需治疗人数为15。
关键数值与推荐
- 标准化HRHF定义:视神经筛板后浸润、大片脉络膜浸润、巩膜浸润、前节受累和/或非大片脉络膜浸润合并筛板前/筛板处视神经浸润。
- 未接受辅助化疗者眼眶肿瘤复发、转移和死亡风险显著增加(P ≤ .002)。
- 孤立性轻微脉络膜浸润合并筛板前/筛板处视神经浸润者需治疗人数为15。
临床怎么用
- 作者推荐初始眼球摘除后诊断为HRHF的患儿使用辅助化疗。
- 作者指出各中心对HRHF定义存在差异并导致不良结局,需要标准化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the clinical outcomes of children with unilateral retinoblastoma (Rb) and high-risk histopathology features (HRHF) following upfront enucleation with/without adjuvant chemotherapy, and investigate cases locally considered non-HRHF but converted to a standardized HRHF definition. DESIGN: Retrospective multinational clinical cohort study. METHODS: Children with Rb who presented to 21 centers from 12 countries between 2011-2020, and underwent primary enucleation were recruited. Centers retrieved clinical data and were asked to report detailed histopathology findings, as well as indicate cases defined locally as high-risk. For analysis, only unilateral cases with standardized HRHF, defined as retrolaminar optic nerve invasion, massive choroidal invasion, scleral invasion, anterior-segment involvement, and/or combined nonmassive choroidal and prelaminar/laminar optic nerve invasion, were included. Main outcome measures included orbital tumor recurrence, systemic metastasis, survival and number, and outcome of cases converted to standardized HRHF. RESULTS: A total of 600 children presenting to 14 centers in 9 countries were included. Of these, 505 (84.2%) were considered locally as HRHF and received adjuvant chemotherapy. After a median follow-up period of 39.2 ± 1.6 months (range: 0.8-60.0 months), 36 (6.0%) had orbital tumor recurrence, 49 (8.2%) metastasis, and 72 (12.0%) children died. Children not receiving adjuvant chemotherapy were at significantly increased risk of orbital tumor recurrence, metastasis, and death (P ≤ .002). Of the study children, 63/600 (10.5%) were considered locally non-HRHF, but converted to standardized HRHF and included in the analysis. Of these, 6/63 (9.5%) had orbital tumor recurrence, 5/63 (7.9%) metastasis, and 6/63 (9.5%) children died. Isolated minor choroidal invasion with prelaminar/laminar optic nerve invasion was reported in 114 (19.0%) children, but considered locally as HRHF only in 68/114 (59.6%). Of these, 6/114 (5.3%) children developed metastasis and subsequently died, yielding a number needed to treat of 15. CONCLUSION: Based on this multinational cohort of children with Rb, we recommend the use of adjuvant chemotherapy following upfront enucleation and diagnosis of HRHF. Variation exists worldwide among centers when defining HRHF, resulting in adverse patient outcomes, warranting standardization.
引用
- Arazi M, Baum A, Casavilca-Zambrano S, et al. Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma. Am J Ophthalmol. 2024. PMID: 39332513. doi:10.1016/j.ajo.2024.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。